StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)

Close on Nov 17, 2026Market cap $10.88MP/E –Yield –

Bolt Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Bolt Biotherapeutics's revenue for the twelve months ending Sep 30, 2026 was $2.53M, down 51.3% year over year. For fiscal 2025 it was $7.70M, up 0.1% from the year before. The highest annual figure on record is $7.88M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.70M+0.1%
FY2024Dec 31, 2024$7.69M-2.4%
FY2023Dec 31, 2023$7.88M+37.5%
FY2022Dec 31, 2022$5.73M+354.7%
FY2021Dec 31, 2021$1.26M+445.5%
FY2020Dec 31, 2020$231.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$5.00K-99.7%
Q1 FY2026Mar 31, 2026$26.00K-97.9%
Q4 FY2025Dec 31, 2025$2.50M–
Q3 FY2025Sep 30, 2025$2.17M+90.1%
Q2 FY2025Jun 30, 2025$1.80M+41.5%
Q1 FY2025Mar 31, 2025$1.22M-76.8%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$1.14M-54.9%
Q2 FY2024Jun 30, 2024$1.28M-11.0%
Q1 FY2024Mar 31, 2024$5.27M+188.8%
Q4 FY2023Dec 31, 2023$2.09M+48.1%
Q3 FY2023Sep 30, 2023$2.53M+19.7%
Q2 FY2023Jun 30, 2023$1.43M+2.9%
Q1 FY2023Mar 31, 2023$1.83M+124.6%
Q4 FY2022Dec 31, 2022$1.41M+177.8%
Q3 FY2022Sep 30, 2022$2.11M+180.9%
Q2 FY2022Jun 30, 2022$1.39M–
Q1 FY2022Mar 31, 2022$813.00K–
Q4 FY2021Dec 31, 2021$508.00K–
Q3 FY2021Sep 30, 2021$752.00K+1022.4%
Q2 FY2021Jun 30, 2021$0-100.0%
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$67.00K–
Q1 FY2020Mar 31, 2020$164.00K–

More Bolt Biotherapeutics figures

See a number that looks wrong?